07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

Arachos Pharma inflammation news

Arachos received a £1.2 million ($1.9 million) award from the U.K. Biomedical Catalyst fund to develop AP362 to treat inflammatory diseases. AP362 is an oral selective glucocorticoid receptor (GCCR) modulator in preclinical testing. Arachos said...